Evidence map›Paper›PMID 34967469›Full record

ArticlePhotodermatology, photoimmunology & photomedicine2022

Carcinogenic effects of prolonged daily low-emission phototherapy in psoriasis.

Sylvie Mireille Franken, Sander Wiebrand Spiekstra, Taco Waaijman, Birgit Lissenberg-Witte, Thomas Rustemeyer

Open access · hybridAbstract read
In one paragraph

Article in Photodermatology, photoimmunology & photomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Carcinogenic effects of prolonged daily low-emission phototherapy in psoriasis.Photodermatology, photoimmunology & photomedicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sylvie Mireille FrankenDepartment of Dermatology, Amsterdam UMC, Amsterdam, the Netherlands.
Sander Wiebrand SpiekstraDepartment of Molecular Cell Biology and Immunology Amsterdam UMC, Amsterdam, the Netherlands.
Taco WaaijmanDepartment of Molecular Cell Biology and Immunology Amsterdam UMC, Amsterdam, the Netherlands.
Birgit Lissenberg-WitteDepartment of Epidemiology and Data Science, Amsterdam UMC, VU Amsterdam, Amsterdam, the Netherlands.
Thomas RustemeyerDepartment of Dermatology, Amsterdam UMC, Amsterdam, the Netherlands.
Amsterdam University Medical Centers · NLAmsterdam Neuroscience · NL

Funding

Dermasun Medical BV
6 · The paper itself

Abstract

backgroundLow-dose UV treatment has been shown to be effective in mild psoriasis. However, the prolonged use of this treatment modality may raise concerns about its safety. These concerns are mainly focused on potential carcinogenic risks and overuse of this treatment modality.

objectivesThis study was set out to evaluate possible carcinogenic risks of prolonged low-dose phototherapy.

methodsThree groups of psoriasis patients were evaluated: patients with local treatment only (n = 15); low-dose UV treatment at home for at least 18 months (n = 39); and patients with conventional NB-UVB (n = 8). Patients underwent visual inspection for signs of photoageing, and p53, CPDs and γH2AX were measured in skin biopsies. Patients undergoing low-dose phototherapy answered a survey about their recent patterns of use in a survey.

resultsIn the skin biopsies, low-dose UV treatment caused a lower amount of CPDs (p = .016) and p53 (p = .015) than NB-UVB. γH2AX did not show a significant difference. Self-report in patients undergoing low-dose phototherapy showed only one case of overuse (2.7%). Visual skin inspection showed no difference in signs of photoageing in the three groups.

conclusionProlonged treatment with low-dose UV for 18 months appears at least as safe as a course of conventional NB-UVB.

Indexed as

PhototherapyPsoriasisSkin AgingUltraviolet TherapyHumansSkinTreatment OutcomeTumor Suppressor Protein p53Tumor Suppressor Protein p53carcinogenic effectslow dose phototherapyp53prolonged usepsoriasisthymidine dimers

Identifiers

PMID34967469
PMCPMC9541771
OpenAlexW4200234203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.